{
    "clinical_study": {
        "@rank": "9853", 
        "arm_group": [
            {
                "arm_group_label": "CSTC1", 
                "arm_group_type": "Active Comparator", 
                "description": "CSTC1 (vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof), topical, two times daily"
            }, 
            {
                "arm_group_label": "CSTC1 Matched vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matched vehicle, topical, two times daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the efficacy and safety of CSTC1 in patient with\n      diabetic foot ulcers."
        }, 
        "brief_title": "CSTC1 for Diabetic Foot Ulcers Phase II Study", 
        "condition": [
            "Diabetic Foot Ulcer", 
            "Diabetes Mellitus", 
            "Wounds"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Ulcer", 
                "Foot Ulcer", 
                "Diabetic Foot"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  With either gender aged at least 20 years old;\n\n          -  With a diabetic ulcer (which is defined as the target ulcer) on the foot and not\n             healing for at least 2 weeks;\n\n          -  The target ulcer is classified as grade 1 or 2 ulcer according to modified Wagner\n             system;\n\n          -  The target ulcer should show \"infection control\" at investigator's discretion;\n\n          -  Subject should be free of any necrosis or infection in soft and bone tissue;\n\n          -  Subject has signed the written informed consent form\n\n        Exclusion Criteria:\n\n          -  With active osteomyelitis;\n\n          -  With target ulcer size decreased by at least 50% after at least 2 weeks of\n             standard-of-care-only period or any other recorded regular therapy before\n             Randomization visit;\n\n          -  With poor nutritional status (albumin < 3g/dl), poor diabetic control (HbA1c > 12%),\n             anemia (hemoglobin<10 g/dL), a leukocyte counts < 1,000/mm3, abnormal liver function\n             (AST, ALT>3 x upper limit of normal range);\n\n          -  Requiring treatment with corticosteroids, immunosuppressive or chemotherapeutic\n             agents;\n\n          -  Presence of necrosis, purulence or sinus tracts that cannot be removed by\n             debridement;\n\n          -  Receiving revascularization surgery performed <8 weeks before entry in the study;\n\n          -  With known or suspected hypersensitivity to any ingredients of study product and\n             vehicle;\n\n          -  With coronary heart disease with myocardial infarction, coronary artery bypass graft\n             (CABG), or percutaneous transluminal coronary angioplasty (PTCA) within 3 months\n             prior to study;\n\n          -  Pregnant or lactating or premenopausal with childbearing potential but not taking\n             reliable contraceptive method(s) during the study period;\n\n          -  Enrollment in any investigational drug trial within 4 weeks before entering this\n             study;\n\n          -  With any uncontrolled illness judged by the investigator that entering the trial may\n             be detrimental to the subject."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813305", 
            "org_study_id": "CSTC1-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "CSTC1", 
                "description": "vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof", 
                "intervention_name": "CSTC1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CSTC1 Matched vehicle", 
                "intervention_name": "CSTC1 Matched vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetic Foot Ulcer", 
            "Diabetes Mellitus", 
            "Debridement", 
            "Standard of Care", 
            "wounds"
        ], 
        "lastchanged_date": "March 13, 2013", 
        "location": {
            "contact": {
                "email": "sushin@kmu.edu.tw", 
                "last_name": "Su-Shin Lee, MD", 
                "phone": "886-7-3208176"
            }, 
            "facility": {
                "address": {
                    "city": "Kaohsiung", 
                    "country": "Taiwan"
                }, 
                "name": "Kaohsiung Medical University Chung-Ho Memorial Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized,Double-Blind,Vehicle-controlled,Parallel,Phase II Study to Evaluate Efficacy and Safety of CSTC1 in Patient With Diabetic Foot Ulcers", 
        "other_outcome": [
            {
                "measure": "Adverse event incidence", 
                "safety_issue": "Yes", 
                "time_frame": "Weeks 1, 2, 3, 4, 6, 8, 10, 12"
            }, 
            {
                "measure": "Change in physical examination results", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12"
            }, 
            {
                "measure": "Net change from baseline in laboratory test results", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12"
            }, 
            {
                "measure": "Net change from baseline in vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12"
            }
        ], 
        "overall_contact": {
            "email": "douglas-chen@tw.asklep.com", 
            "last_name": "Shr-Wei Chen, MS", 
            "phone": "886-2-23810366", 
            "phone_ext": "103"
        }, 
        "overall_official": {
            "affiliation": "Kaohsiung Medical University Chung-Ho Memorial Hospital", 
            "last_name": "Su-Shin Lee, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Taiwan : Food and Drug Administration", 
                "Taiwan: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Complete ulcer closure is defined as 100% skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart.", 
            "measure": "Incidence of complete ulcer closure during up to 12 weeks of treatment period", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813305"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Defined as the time to complete ulcer closure", 
                "measure": "The ulcer closure time", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Defined as the time to half ulcer closure", 
                "measure": "The half ulcer closure time (CT50)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The proportion of ulcer closure at each post-treatment visit", 
                "measure": "The ulcer closure rate", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1, 2, 3, 4, 6, 8, 10, 12"
            }, 
            {
                "description": "The ulcer size at each post-treatment visit minus the ulcer size at baseline", 
                "measure": "Change from baseline in ulcer size", 
                "safety_issue": "No", 
                "time_frame": "Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12"
            }, 
            {
                "description": "Calculated as (Ulcer size at post treatment visit - Ulcer size at baseline)/(Ulcer size at baseline)", 
                "measure": "Percentage change in ulcer size for each post-treatment visit", 
                "safety_issue": "No", 
                "time_frame": "Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12"
            }
        ], 
        "source": "Charsire Biotechnology Corp.", 
        "sponsors": {
            "collaborator": {
                "agency": "ASKLEP Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Charsire Biotechnology Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}